Apart from Daiichi, a growing number of drugmakers have elected to part ways with their over-the-counter businesses in recent ...
Despite a new supply commitment from Gilead Sciences, Doctors Without Borders/Médecins Sans Frontières (MSF) is poking holes ...
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the ...
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
For Astellas’ chief manufacturing officer Rao Mantri, Ph.D.—who entered the position a little over a year ago—production is ...
Actress, producer, and artist Lucy Liu has joined Pfizer’s mission to deliver a knockout blow against cancer, becoming the ...
Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers ...
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...
Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...
As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting ...
Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...
The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results